AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22049950 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppered injections
Number of subjects: 19
Study 18832042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial bolus of 40 microg PGE1 in addition to angioplasty
Number of subjects: 45
Study 18832042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 40 microg PGE1
Number of subjects: 45
Study 18832042 — intervention group
Group type: COMPARATOR
Intervention: Control group (no trial medication)
Number of subjects: 45
Study 17335532 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 408
Study 17335532 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 408
Study 17335532 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-fowler position
Number of subjects: 408
Study 17335532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting up position
Number of subjects: 408
Study 15257087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (6 mL/kg)
Number of subjects: 14
Study 15257087 — intervention group
Group type: COMPARATOR
Intervention: High tidal volume (12 mL/kg)
Number of subjects: 14
Study 12385679 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ciprofloxacin
Number of subjects: 0
Study 12385679 — intervention group
Group type: COMPARATOR
Intervention: 500 mg ciprofloxacin
Number of subjects: 0
Study 10087818 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous PKF (propofol 2‐10 mg.kg‐1.h‐1, ketamine 240 micrograms.kg‐1.h‐1 and fentanyl 0.4 microgram.kg‐1.h‐1)
Number of subjects: 22
Study 10087818 — intervention group
Group type: COMPARATOR
Intervention: GOI (N2O‐oxygen‐isoflurane)
Number of subjects: 22
Study 7553406 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg, single intravenous dose)
Number of subjects: 40
Study 7553406 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (2 mg/kg, multiple doses)
Number of subjects: 40
Study 2111768 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) discontinuation
Number of subjects: 70
Study 2111768 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA) discontinuation
Number of subjects: 70
Study 2111768 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT) discontinuation
Number of subjects: 70
Study 2111768 — intervention group
Group type: COMPARATOR
Intervention: Control group (stable therapy)
Number of subjects: 70
Study 415439 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of 5-10 mmol phosphate (155-310 mg phosphorus) per 1000 kcal of nutrient solution during parenteral nutrition.
Number of subjects: 0
Study 415439 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased phosphate dosage for hypophosphatemic patients with acute renal insufficiency.
Number of subjects: 0
Study 415439 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phosphate determination at the start of parenteral nutrition and every second day during the first week.
Number of subjects: 0
Study 415439 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phosphate determination twice weekly after the first week of parenteral nutrition.
Number of subjects: 0
Study 30407513 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA‐EBO‐Z alone or in a heterologous prime‐boost regimen with ChAd3‐EBO‐Z
Number of subjects: 78
Study 30407513 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd3‐EBO‐Z followed by MVA‐EBO‐Z
Number of subjects: 78
Study 30407513 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated 1‐week prime‐boost regimen
Number of subjects: 78
Study 30407513 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA‐EBO‐Z
Number of subjects: 78
Study 28632595 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 614
Study 28632595 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 614
Study 26362623 — intervention group
Group type: EXPERIMENTAL
Intervention: Total pericardial closure with intrapericardial drain and pericardio-pleural window (closure group)
Number of subjects: 142
Study 26362623 — intervention group
Group type: COMPARATOR
Intervention: Partial closure of the pericardium (open group)
Number of subjects: 142
Study 23855596 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training (75-90% 1RM)
Number of subjects: 372
Study 23855596 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity strength training (30-40% 1RM)
Number of subjects: 372
Study 23855596 — intervention group
Group type: COMPARATOR
Intervention: Healthy living education
Number of subjects: 372
Study 23855596 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training
Number of subjects: 372
Study 23855596 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity strength training
Number of subjects: 372
Study 21463068 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 193
Study 21463068 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 193
Study 21463068 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Alcohol Dependence (AD)
Number of subjects: 193
Study 21463068 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Alcohol Dependence (non-AD)
Number of subjects: 193
Study 19802926 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised functional training programme (100 hours)
Number of subjects: 25
Study 16886934 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 169
Study 16886934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 16886934 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent stress-management therapy
Number of subjects: 169
Study 16886934 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication and placebo (irrespective of drug condition)
Number of subjects: 169
Study 16886934 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologists' ratings of improvement, participants' reports of improvement, daily headache recordings
Number of subjects: 169
Study 15174784 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 microg twice daily
Number of subjects: 19
Study 15174784 — intervention group
Group type: COMPARATOR
Intervention: Treatment-free period
Number of subjects: 19
Study 15174784 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide treatment
Number of subjects: 19
Study 12010587 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (OO)
Number of subjects: 18
Study 12010587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower-seed oil (SO)
Number of subjects: 18
Study 12010587 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil (RO)
Number of subjects: 18
Study 9475646 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (1200 IUs once a day for 2 weeks)
Number of subjects: 12
Study 9475646 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose‐based placebo pills once a day for 2 weeks)
Number of subjects: 12
Study 8560135 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa 100-200 mg
Number of subjects: 28
Study 2227131 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet (1200 kcal/day)
Number of subjects: 12
Study 2227131 — intervention group
Group type: COMPARATOR
Intervention: Control diet (2400 kcal/day)
Number of subjects: 12
Study 339933 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8
Study 339933 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study 29100842 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 90
Study 29100842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (participants' own faeces)
Number of subjects: 90
Study 27138964 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C15-PAL module (anchor-based approach)
Number of subjects: 204
Study 27138964 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-BM22 and QLQ-C15-PAL QOL instruments
Number of subjects: 204
Study 27138964 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C15-PAL module (distribution-based approach)
Number of subjects: 204
Study 24846364 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial (TR) approach
Number of subjects: 103
Study 24846364 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral (TF) approach
Number of subjects: 103
Study 21930686 — intervention group
Group type: EXPERIMENTAL
Intervention: IMM-101 0.1 mg (1 mg/ml)
Number of subjects: 18
Study 21930686 — intervention group
Group type: EXPERIMENTAL
Intervention: IMM-101 0.5 mg (5 mg/ml)
Number of subjects: 18
Study 21930686 — intervention group
Group type: EXPERIMENTAL
Intervention: IMM-101 1.0 mg (10 mg/ml)
Number of subjects: 18
Study 21930686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21930686 — intervention group
Group type: EXPERIMENTAL
Intervention: IMM-101 (all doses)
Number of subjects: 18
Study 21045228 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning
Number of subjects: 30
Study 21045228 — intervention group
Group type: COMPARATOR
Intervention: Text reading only
Number of subjects: 30
Study 21045228 — intervention group
Group type: COMPARATOR
Intervention: Text reading and video demonstration
Number of subjects: 30
Study 17655512 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam ODT 1.0 mg under fasting conditions
Number of subjects: 16
Study 17655512 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam ODT 1.0 mg after a standard high-fat breakfast
Number of subjects: 16
Study 16278574 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training curriculum provided in a small group residential format over a 4-day period.
Number of subjects: 64
Study 16278574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 64
Study 12151926 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH group (5-8 ml/kg of blood withdrawn before systemic heparinization and replaced with colloid solutions)
Number of subjects: 204
Study 12151926 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hemodilution performed)
Number of subjects: 204
Study 10495621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholagogum F Nattermann (dried extracts from Schöllkraut and Curcuma)
Number of subjects: 76
Study 10495621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 7492867 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 119
Study 7492867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 7492867 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 119
Study 1938512 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus 2100 cGy to the liver
Number of subjects: 300
Study 1938512 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 300
Study 6756155 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% prednisolone phosphate eyedrops
Number of subjects: 11
Study 6756155 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 11
Study 31469080 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based peer-support intervention program (PIP)
Number of subjects: 20
Study 31469080 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20
Study 27677771 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 155
Study 26370552 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 1352
Study 26370552 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 1352
Study 26370552 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1352
Study 24468996 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-Immediate
Number of subjects: 0
Study 24468996 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-Def
Number of subjects: 0
Study 24468996 — intervention group
Group type: COMPARATOR
Intervention: HUU
Number of subjects: 0
Study 24468996 — intervention group
Group type: COMPARATOR
Intervention: HEU
Number of subjects: 0
Study 24468996 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of ART initiation
Number of subjects: 0
Study 22583789 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-FIT intervention (computer-tailored lifestyle advice and counselling)
Number of subjects: 181
Study 22583789 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-FIT*advice log
Number of subjects: 181
Study 22583789 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face counselling sessions
Number of subjects: 181
Study 22583789 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone booster calls
Number of subjects: 181
Study 20425223 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA) administered within 4.5 hours of symptom onset
Number of subjects: 0
Study 20425223 — intervention group
Group type: COMPARATOR
Intervention: Recombinant tissue plasminogen activator (rt-PA) administered within 3 hours of symptom onset
Number of subjects: 0
Study 17406114 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized multimedia computer program (IMCP)
Number of subjects: 57
Study 17406114 — intervention group
Group type: COMPARATOR
Intervention: Standard information from treating neurologist
Number of subjects: 57
Study 17406114 — intervention group
Group type: COMPARATOR
Intervention: General knowledge of vascular risk factors
Number of subjects: 57
Study 17406114 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of treatment modalities
Number of subjects: 57
Study 15750363 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal supplement for a 2-week period
Number of subjects: 37174
Study 15750363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no herbal supplement)
Number of subjects: 37174
Study 11902251 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prostacyclin (2 ng/kg/min) added to the standard anesthetic protocol, started immediately before surgery and continued for a maximum of 48 hours.
Number of subjects: 34
Study 11902251 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard anesthetic protocol without prostacyclin)
Number of subjects: 34
Study 11902251 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prostacyclin (2 ng/kg/min)
Number of subjects: 34
Study 10468073 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation after catheter recanalization
Number of subjects: 110
Study 10468073 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty alone (no stent group)
Number of subjects: 110
Study 8654903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening tasks (verbal and nonverbal paradigms)
Number of subjects: 4
Study 8654903 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly persons with marked dichotic deficits
Number of subjects: 4
Study 8654903 — intervention group
Group type: COMPARATOR
Intervention: Young adults with normal hearing
Number of subjects: 4
Study 1331444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 110
Study 1331444 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 110
Study 1331444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 3001952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 61
Study 3001952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 31401532 — intervention group
Group type: EXPERIMENTAL
Intervention: Own brand cigarette (OB)
Number of subjects: 7
Study 31401532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco/Menthol 36 mg/ml ECIG
Number of subjects: 7
Study 31401532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco/Menthol 0 mg/ml ECIG
Number of subjects: 7
Study 31401532 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 mg/ml ECIG
Number of subjects: 7
Study 31401532 — intervention group
Group type: EXPERIMENTAL
Intervention: ECIG conditions
Number of subjects: 7
Study 31401532 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing conditions
Number of subjects: 7
Study 31401532 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavors
Number of subjects: 7
Study 29106497 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 69
Study 29106497 — intervention group
Group type: COMPARATOR
Intervention: No Candesartan (Control)
Number of subjects: 69
Study 29106497 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative doxorubicin equivalent dose ≥268 mg/m2
Number of subjects: 69
Study 29106497 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline therapy
Number of subjects: 69
Study 26735316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-Stand Workstation (SSW)
Number of subjects: 46
Study 26423621 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin in SAD study
Number of subjects: 49
Study 26423621 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin in TQT study
Number of subjects: 49
Study 23909550 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDF with Cloward procedure or cervical intervertebral fusion cage
Number of subjects: 73
Study 23909550 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDF
Number of subjects: 73
Study 21368271 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 supplementation
Number of subjects: 18
Study 21368271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 18
Study 18210092 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition introduced immediately at optimal flow rate (25 Kcal/kg day(‐1))
Number of subjects: 100
Study 18210092 — intervention group
Group type: COMPARATOR
Intervention: Early enteral nutrition introduced gradually to reach optimal flow rate
Number of subjects: 100
Study 16551764 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about diagnosis
Number of subjects: 1271
Study 16551764 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about poor prognosis
Number of subjects: 1271
Study 16551764 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of diagnosis (non-informed)
Number of subjects: 1271
Study 16551764 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of poor prognosis (non-informed)
Number of subjects: 1271
Study 16551764 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with being informed
Number of subjects: 1271
Study 12672170 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 41
Study 12672170 — intervention group
Group type: COMPARATOR
Intervention: Vitex agnus castus (AC) extract
Number of subjects: 41
Study 10568767 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinia-vectored vaccine; subcutaneous inoculation of approximately 10^7 plaque-forming units; administered in two doses at 4-week intervals.
Number of subjects: 158
Study 10568767 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group); administered in a double-blinded manner.
Number of subjects: 158
Study 9446348 — intervention group
Group type: EXPERIMENTAL
Intervention: SAA content measured postoperatively
Number of subjects: 20
Study 9446348 — intervention group
Group type: EXPERIMENTAL
Intervention: SAA content in patients after pulmonectomy
Number of subjects: 20
Study 9446348 — intervention group
Group type: EXPERIMENTAL
Intervention: SAA content in patients after lobectomy
Number of subjects: 20
Study 9446348 — intervention group
Group type: EXPERIMENTAL
Intervention: SAA content in patients after thoracotomy
Number of subjects: 20
Study 9446348 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 healthy volunteers)
Number of subjects: 20
Study 7970441 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 27
Study 7970441 — intervention group
Group type: COMPARATOR
Intervention: Radionuclide ventriculography
Number of subjects: 27
Study 7970441 — intervention group
Group type: COMPARATOR
Intervention: Total coronary occlusions
Number of subjects: 27
Study 3594319 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms via aerosol)
Number of subjects: 3
Study 3594319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 3594319 — intervention group
Group type: COMPARATOR
Intervention: No pre-medication (control)
Number of subjects: 3
Study 31551136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand massage (10-minute duration) before cataract surgery
Number of subjects: 140
Study 31551136 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (control group)
Number of subjects: 140
Study 30541643 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective brain hypothermia (SBH) treatment
Number of subjects: 40
Study 30541643 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 40
Study 26806248 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted technique (group B)
Number of subjects: 6
Study 26806248 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic technique (group A)
Number of subjects: 6
Study 25154045 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam for inhalation solution (AZLI) 75 mg, three-times daily for two 4-week courses
Number of subjects: 268
Study 25154045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 22677166 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCD Parenting Young Adolescent Program
Number of subjects: 180
Study 20102875 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hematomas ≥5 cm
Number of subjects: 3342
Study 20102875 — intervention group
Group type: COMPARATOR
Intervention: Patients without hematomas ≥5 cm
Number of subjects: 3342
Study 18073554 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose smoked cannabis (4% 9-delta-tetrahydrocannabinol)
Number of subjects: 15
Study 18073554 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose smoked cannabis (8% 9-delta-tetrahydrocannabinol)
Number of subjects: 15
Study 18073554 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose smoked cannabis (2% 9-delta-tetrahydrocannabinol)
Number of subjects: 15